<DOC>
	<DOCNO>NCT02604355</DOCNO>
	<brief_summary>This multiple-center , randomize , double-blind , placebo-controlled , single-ascending dose multiple-ascending dose , adaptive parallel study investigate safety , tolerability , pharmacokinetics pharmacodynamics RO7020322 follow oral administration healthy participant chronic hepatitis B patient .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics RO7020322 Following Oral Administration Healthy Participants Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Healthy Participants ' A Body Mass Index ( BMI ) 18 30 kg/m^2 , inclusive , body weight least 50 kg Males must agree remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agree refrain donate sperm study Women nonchildbearing potential Able comply study restriction Nonsmoker ( tobaccocontaining product ) least 90 day prior dose Day 1 agree smoke study Chronic Hepatitis BInfected Participants ' Chronic hepatitis B infection A BMI 18 32 kg/m^2 , inclusive Positive test HBsAg 6 month prior randomization On entecavir tenofovir treatment least 6 month prior randomization remain stable treatment study Liver biopsy , fibroscanÂ® equivalent test obtain within past 6 month demonstrate liver disease consistent chronic hepatitis B ( HBV ) infection without evidence bridge fibrosis cirrhosis Males must agree remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agree refrain donate sperm study Women childbearing potential must agree remain abstinent ( refrain heterosexual intercourse ) use nonhormonal contraceptive method result failure rate &lt; 1 % per year treatment period least end followup period Healthy Participants ' Women lactate Any suspicion history alcohol and/or substance abuse dependence past 6 month Positive urine drug alcohol screen ( barbiturate , benzodiazepine , methadone , amphetamine , methamphetamine , opiate , cocaine , cannabinoids , alcohol ) , positive cotinine test Day 1 Positive result HBV , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) 1 2 A personal history unexplained blackout faint , know risk factor Torsade de Pointes Clinically significant abnormality ( judged Investigator ) physical examination laboratory test result ( include hepatic renal panel , complete blood count , chemistry panel urinalysis ) screen Day 1 Participation investigational drug device study within 90 day prior screen 5 time halflife investigational drug ( whichever longer ) Donation blood 500 mL within three month prior screen Concomitant disease condition ( include allergic reaction drug , multiple allergy ) could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk healthy participant study Chronic Hepatitis BInfected Participants ' Women pregnant ( positive pregnancy test ) lactate History evidence bleed esophageal varix Decompensated liver disease History evidence medical condition associate chronic liver disease HBV infection Documented history evidence metabolic liver disease within one year randomization Positive test hepatitis A ( IgM antiHAV ) , hepatitis C , HIV Documented history infection hepatitis D virus Expected need systemic antiviral therapy provide study time participation study , exception oral therapy herpes simplex virus ( HSV ) I HSV II History immunologicallymediated disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>